Registro:

Referencias:

• Asa, S.L., Kelly, M.A., Grandy, D.K., Low, M.J., Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice (1999) Endocrinology, 140, pp. 5348-5355
• Banerjee, S.K., Sarkar, D.K., Weston, A.P., De A, Campbell, D.R., Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis (1997) Carcinogenesis, 18 (6), pp. 1155-1161. , DOI 10.1093/carcin/18.6.1155
• Banerjee, S.K., Zoubine, M.N., Tran, T.M., Weston, A.P., Campbell, D.R., Overexpression of vascular endothelial growth factor164 and its co-receptor neuropilin-1 in estrogen-induced rat pituitary tumors and GH3 rat pituitary tumor cells (2000) Int J Oncol, 16, pp. 253-260
• Basu, S., Nagy, J.A., Pal, S., Vasile, E., Eckelhoefer, I.A., Bliss, V.S., Manseau, E.J., Mukhopadhyay, D., The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor (2001) Nature Medicine, 7 (5), pp. 569-574. , DOI 10.1038/87895
• Batchelor, T.T., Sorensen, A.G., Di, T.E., Zhang, W.-T., Duda, D.G., Cohen, K.S., Kozak, K.R., Jain, R.K., AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients (2007) Cancer Cell, 11 (1), pp. 83-95. , DOI 10.1016/j.ccr.2006.11.021, PII S1535610806003709
• Ben-Jonathan, N., Hnasko, R., Dopamine as a prolactin (PRL) inhibitor (2001) Endocrine Reviews, 22 (6), pp. 724-763. , DOI 10.1210/er.22.6.724
• Burris III, H., Rocha-Lima, C., New therapeutic directions for advanced pancreatic cancer: Targeting the epidermal growth factor and vascular endothelial growth factor pathways (2008) Oncologist, 13, pp. 289-298
• Caccavelli, L., Morange-Ramos, I., Kordon, C., Jaquet, P., Enjalbert, A., Alteration of Gα subunits mRNA levels in bromocriptine resistant prolactinomas (1996) Journal of Neuroendocrinology, 8 (10), pp. 737-746
• Crawford, Y., Ferrara, N., VEGF inhibition: Insights from preclinical and clinical studies (2009) Cell Tissue Res, 335, pp. 261-269
• Cristina, C., Diaz-Torga, G., Baldi, A., Gongora, A., Rubinstein, M., Low, M.J., Becu-Villalobos, D., Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice (2005) Endocrinology, 146 (7), pp. 2952-2962. , http://endo.endojournals.org/cgi/reprint/146/7/2952, DOI 10.1210/en.2004-1445
• Cristina, C., Garcia-Tornadu, I., Diaz-Torga, G., Rubinstein, M., Low, M.J., Becu-Villalobos, D., Dopaminergic D2 receptor knockout mouse: An animal model of prolactinoma (2006) Frontiers of Hormone Research, 35, pp. 50-63. , DOI 10.1159/000094308, Pituitary Today: Molecular, Physiological and Clinical Aspects
• Cristina, C., Perez-Millan, M.I., Luque, G., Dulce, R.A., Sevlever, G., Berner, S.I., Becu-Villalobos, D., VEGF and CD31 association in pituitary adenomas (2010) Endocr Pathol, 21, pp. 154-160
• Di Ieva, A., Grizzi, F., Gaetani, P., Goglia, U., Tschabitscher, M., Mortini, P., Rodriguez Y Baena, R., Euclidean and fractal geometry of microvascular networks in normal and neoplastic pituitary tissue (2008) Neurosurg Rev, 31, pp. 271-281
• Ferrara, N., Pathways mediating VEGF-independent tumor angiogenesis (2010) Cytokine Growth Factor Rev, 21, pp. 21-26
• Folkman, J., Shing, Y., Angiogenesis (1992) J Biol Chem, 267, pp. 10931-10934
• Fong, T.A.T., Shawver, L.K., Sun, L., Tang, C., App, H., Powell, T.J., Kim, Y.H., McMahon, G., SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types (1999) Cancer Research, 59 (1), pp. 99-106
• Gerber, H.-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B.A., Dixit, V., Ferrara, N., Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway: Requirement for Flk-1/KDR activation (1998) Journal of Biological Chemistry, 273 (46), pp. 30336-30343. , DOI 10.1074/jbc.273.46.30336
• Hoeben, A., Landuyt, B., Highley, M.S., Wildiers, H., Van Oosterom, A.T., De Bruijn, E.A., Vascular endothelial growth factor and angiogenesis (2004) Pharmacological Reviews, 56 (4), pp. 549-580. , DOI 10.1124/pr.56.4.3
• Jugenburg, M., Kovacs, K., Stefaneanu, L., Scheithauer, B.W., Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: A quantitative morphologic study (1995) Endocr Pathol, 6, pp. 115-124
• Kelly, M.A., Rubinstein, M., Asa, S.L., Zhang, G., Saez, C., Bunzow, J.R., Allen, R.G., Low, M.J., Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice (1997) Neuron, 19 (1), pp. 103-113. , DOI 10.1016/S0896-6273(00)80351-7
• Kerbel, R.S., Tumor angiogenesis (2008) N Engl J Med, 358, pp. 2039-2049
• Kim, K., Yoshida, D., Teramoto, A., Expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in pituitary adenomas (2005) Endocrine Pathology, 16 (2), pp. 115-121. , DOI 10.1385/EP:16:2:115
• Komorowski, J., Jankewicz, J., Stepień, H., Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours (2000) Cytobios, 101, pp. 151-159
• Korsisaari, N., Ross, J., Wu, X., Kowanetz, M., Pal, N., Hall, L., Eastham-Anderson, J., Ferrara, N., Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1 (2008) Clinical Cancer Research, 14 (1), pp. 249-258. , http://clincancerres.aacrjournals.org/cgi/reprint/14/1/249, DOI 10.1158/1078-0432.CCR-07-1552
• Liang, W.C., Wu, X., Peale, F.V., Lee, C.V., Meng, Y.G., Gutierrez, J., Fu, L., Ferrara, N., Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF (2006) J Biol Chem, 281, pp. 951-961
• Lloyd, R.V., Scheithauer, B.W., Kuroki, T., Vidal, S., Kovacs, K., Stefaneanu, L., Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas (1999) Endocr Pathol, 10, pp. 229-235
• Lohrer, P., Gloddek, J., Hopfner, U., Losa, M., Uhl, E., Pagotto, U., Stalla, G.K., Renner, U., Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro (2001) Neuroendocrinology, 74 (2), pp. 95-105. , DOI 10.1159/000054675
• McCabe, C.J., Boelaert, K., Tannahill, L.A., Heaney, A.P., Stratford, A.L., Khaira, J.S., Hussain, S., Gittoes, N.J., Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors (2002) J Clin Endocrinol Metab, 87, pp. 4238-4244
• Molitch, M.E., Pharmacologic resistance in prolactinoma patients (2005) Pituitary, 8, pp. 43-52
• Mori, J., Haisa, M., Naomoto, Y., Takaoka, M., Kimura, M., Yamatsuji, T., Notohara, K., Tanaka, N., Suppression of tumor growth and downregulation of platelet-derived endothelial cell growth factor/thymidine phosphorylase in tumor cells by angiogenesis inhibitor TNP-470 (2000) Japanese Journal of Cancer Research, 91 (6), pp. 643-650
• Ochoa, A.L., Mitchner, N.A., Paynter, C.D., Morris, R.E., Ben-Jonathan, N., Vascular endothelial growth factor in the rat pituitary: Differential distribution and regulation by estrogen (2000) Journal of Endocrinology, 165 (2), pp. 483-492
• Onofri, C., Carbia, N.A., Schaaf, L., Feirer, M., Lohrer, P., Stummer, W., Berner, S., Arzt, E., Estradiol Stimulates Vascular Endothelial Growth Factor and Interleukin-6 in Human Lactotroph and Lactosomatotroph Pituitary Adenomas (2004) Experimental and Clinical Endocrinology and Diabetes, 112 (1), pp. 18-23. , DOI 10.1055/s-2004-815722
• Pellegrini, I., Rasolonjanahary, R., Gunz, G., Bertrand, P., Delivet, S., Jedynak, C.P., Kordon, C., Enjalbert, A., Resistance to bromocriptine in prolactinomas (1989) Journal of Clinical Endocrinology and Metabolism, 69 (3), pp. 500-509
• Pizarro, C.B., Oliveira, M.C., Pereira-Lima, J.F., Leães, C.G., Kramer, C.K., Schuch, T., Barbosa-Coutinho, L.M., Ferreira, N.P., Evaluation of angiogenesis in 77 pituitary adenomas using endoglin as a marker (2009) Neuropathology, 29, pp. 40-44
• Reynolds, L.P., Grazul-Bilska, A.T., Redmer, D.A., Angiogenesis in the corpus luteum (2000) Endocrine, 12 (1), pp. 1-9
• Schechter, J., Ultrastructural changes in the capillary bed of human pituitary tumors (1972) Am J Pathol, 67, pp. 109-126
• Teunis, M.A., Kavelaars, A., Voest, E., Bakker, J.M., Ellenbroek, B.A., Cools, A.R., Heijnen, C.J., Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system (2002) FASEB J, 16, pp. 1465-1467
• Turner, H.E., Harris, A.L., Melmed, S., Wass, J.A.H., Angiogenesis in Endocrine Tumors (2003) Endocrine Reviews, 24 (5), pp. 600-632. , DOI 10.1210/er.2002-0008
• Vidal, S., Lloyd, R.V., Moya, L., Scheithauer, B.W., Kovacs, K., Expression and distribution of vascular endothelial growth factor receptor Flk-1 in the rat pituitary (2002) Journal of Histochemistry and Cytochemistry, 50 (4), pp. 533-540
• Wulff, C., Wiegand, S.J., Saunders, P.T.K., Scobie, G.A., Fraser, H.M., Angiogenesis during follicular development in the primate and its inhibition by treatment with truncated Flt-1-Fc (Vascular Endothelial Growth Factor TrapA40) (2001) Endocrinology, 142 (7), pp. 3244-3254. , DOI 10.1210/en.142.7.3244

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------